key: cord-0781197-a9vy9jeq
authors: Grandolfo, Mauro; Romita, Paolo; Bonamonte, Domenico; Cazzato, Gerardo; Hansel, Katharina; Stingeni, Luca; Conforti, Claudio; Giuffrida, Roberta; Foti, Caterina
title: Drug reaction with eosinophilia and systemic symptoms syndrome to hydroxychloroquine, an old drug in the spotlight in the COVID‐19 era
date: 2020-05-22
journal: Dermatol Ther
DOI: 10.1111/dth.13499
sha: 470c5ca9fff0307a0495f58460a25f10b8ac98b9
doc_id: 781197
cord_uid: a9vy9jeq

nan

Other serological investigations (antinuclear antibodies, serology for HAV/HBV/HCV and EBV, antibodies to chlamydia/mycoplasma) F I G U R E 1 Generalized maculopapular eruption associated to erythema multiforme-like aspect on the lower limbs with massive exfoliation in a 69-year-old woman

Drug reaction with eosinophilia and systemic symptoms caused by lenalidomide

Drug reaction with eosinophilia and systemic symptoms from ceftriaxone confirmed by positive patch test: an immunohistochemical study

Pustular DRESS syndrome secondary to hydroxychloroquine with EBV reactivation

Generalized pustular figurate erythema: a newly delineated severe cutaneous drug reaction linked with hydroxychloroquine

Drug reaction with eosinophilia and systemic symptoms (DRESS): an interplay among drugs, viruses, and immune system

Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial

Doxycycline, a widely used antibiotic in dermatology with a possible anti-inflammatory action against IL-6 in COVID-19 outbreak

COVID-19 and psoriasis: is it time to limit treatment with immunosuppressants? A call for action